Lesinurad
Indication
Treating chronic hyperuricaemia in people with gout (NICE TA506)
NICE TA506 - Lesinurad for treating chronic hyperuricaemia in people with gout
Black
Brand:
Zurampic®
Nice TA:
506
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Musculoskeletal system
Background
Lesinurad is not recommended within its marketing authorisation, that is, with a xanthine oxidase inhibitor for treating hyperuricaemia in adults with gout whose serum uric acid is above the target level despite an adequate dose of a xanthine oxidase inhibitor alone.
Recommendation
LSCMMG Recommendation:
Black
Reason for decision:
Not recommended for prescribing on the NHS in Lancashire & South Cumbria
Supporting documents: